Similar articles

• [Humoral response to Epstein-Barr virus of patients with nasopharyngeal cancer and its use in the differential diagnosis of the disease].

  Gurtsevich VE, Plakhov IV, Chuĭkina NA, Abdulin NA. Gurtsevich VE, et al. Vestn Akad Med Nauk SSSR. 1984;(5):29-34. Vestn Akad Med Nauk SSSR. 1984. PMID: 6331022 Russian. No abstract available.
• Anti-EBV antibody titers in Italian patients with nasopharyngeal carcinoma.

  Pirodda E, Caliceti U, Testoni S. Pirodda E, et al. J Exp Pathol. 1987 Summer;3(4):479-83. J Exp Pathol. 1987. PMID: 2842481
• Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls.

  Henle W, Henle G, Ho JH. Henle W, et al. IARC Sci Publ (1971). 1978;(20):427-37. IARC Sci Publ (1971). 1978. PMID: 215525 No abstract available.
• The epidemiology of EBV-associated malignant diseases.

  Levine PH. Levine PH. J Exp Pathol. 1987 Summer;3(4):437-9. J Exp Pathol. 1987. PMID: 2842475 Review. No abstract available.
• [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].

  Mazeron MC. Mazeron MC. Bull Cancer Radiother. 1996;83(1):3-7. Bull Cancer Radiother. 1996. PMID: 8679277 Review. French.